A Phase 1 Study of the Safety and Tolerability of CTX-10726
← catalyst calendarNCT07419841 · readout in 591 d
Sponsored by Compass Therapeutics (industry) · CMPX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
70estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-28 | actual | When the study began enrolling |
| Primary completion | 2028-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastroesophageal Cancer (GC)
- Hepatocellular Carcinoma (HCC)
- Endometrial Cancer
- Renal Cell Carcinoma (RCC)
Intervention
- Drug: CTX-10726
Primary outcomes
what the primary-completion date above is the date OFCohort 1: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) in escalating doses
measured From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726, average of 6 months)
Cohort 1: Determine the dose(s) of CTX-10726 to be further examined in Cohort 2 and Phase 2 studies
measured From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks ) until 30 days after the last dose of CTX-10726 (average of 6 months)
Cohort 2: Evaluate the safety and tolerability of CTX-10726 by incidence of treatment-emergent adverse events (TEAEs) at dose(s) selected from Cohort 1
measured From first dose of CTX-10726 (Cycle 1 Day 1, Cycle = 2 weeks) until 30 days after the last dose of CTX-10726 (up to 2 years)
Permalink · CMPX's whole pipeline · Catalyst calendar · Every registered study · What changed